Bio-Thera Solutions and Tabuk Pharmaceuticals Join Forces to Commercialize BAT2206 (Biosimilar, Stelara) in Saudi Arabia
Shots:
- Bio-Thera Solutions has collaborated with Tabuk Pharmaceuticals to commercialize BAT2206, biosimilar of Stelara (Ustekinumab) in Saudi Arabia
- The alliance will utilize Tabuk's local footprint, sales & marketing abilities, with Tabuk handling marketing, registration, manufacturing & promotion of BAT2206. Bio-Thera will manage development & supply from its Guangzhou manufacturing facilities
- BAT2206, a proposed biosimilar to Janssen's Stelara, is a human mAb that targets IL-12 & IL-23 by inhibiting p40 binding to IL-12Rβ1 on immune cells. Bio-Thera has filed for regulatory approval with the US FDA, EMA & NMPA
Ref: Bio-Thera Solutions | Image: Bio-Thera Solutions & Tabuk Pharmaceuticals
Related News:- Bio-Thera Solutions and SteinCares Add Another Biosimilar, Expanding their Alliance
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
